EUVIMEDEUVIMED entdecken
Crossref

Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection

Seong Kwon Hur, Rebecca R Leahey, Mitchell Geringer, Chang Hoon Cho, Hilda Hernandez-Barry, Jichu Pang, William S Sawyer, Miriam Baca, Marika Nespi, Raymond R Asuncion, ManKin Choy, James Maksymetz und 11 weitere

Journal of Neuropathology & Experimental Neurology · 2025

DOI: 10.1093/jnen/nlaf066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2025. Verfasst von Seong Kwon Hur und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Genentech, Inc., South San Francisco, CA, United States. Hauptthemen laut MEDLINE: Armadillo Domain Proteins, Cytoskeletal Proteins, Action Potentials, Sciatic Nerve. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Genentech.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The NADase sterile alpha and TIR motif containing 1 (Sarm1) protein drives axon degeneration after injury. Loss or inhibition of Sarm1 structurally protects axons after sciatic nerve transection (SNT) in vivo but whether Sarm1 also drives functional loss after nerve injury is less clear. We established compound muscle action potential (CMAP) as a novel functional correlate of Sarm1 activation in a SNT mouse model and evaluated its relationship with biochemical and a novel Cellpose-based histological axon detection measure. CMAP amplitudes were elicited 8 h post-SNT but reached near-floor levels by 24 h. Decreases in CMAP amplitude are delayed in a gene dose-dependent manner in Sarm1 knockout mice or by pharmacological Sarm1 inhibition. Myelinated axon density, the NAD hydrolysis product cyclic adenosine diphosphate ribose (cADPR), and the axon degeneration plasma biomarker neurofilament light (NfL) were all altered in a Sarm1-dependent manner. In wild type mice, axon density and NfL were altered at time points after that of cADPR and functional loss, indicating that functional deficits preceded structural deficits. We conclude that functional and structural declines after injury are delayed by Sarm1 inhibition and that CMAP measures after SNT can serve as a novel, preclinical, functional, pharmacodynamic readout for Sarm1 inhibition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Armadillo Domain ProteinsCytoskeletal ProteinsAction PotentialsSciatic NerveSciatic NeuropathyMuscle, SkeletalAnimalsMiceMice, KnockoutMice, Inbred C57BLMaleAxons

Stichwörter der Autor:innen

CMAPSarm1 inhibitoraxon degenerationaxon densitybiomarkercADPRneurofilament light (NfL)

Substanzen

Armadillo Domain ProteinsSARM1 protein, mouseCytoskeletal Proteins

Autor:innen und Institutionen

  • Department of Neuroscience, Genentech, Inc., South San Francisco, CA, United States.
  • Department of Pathology, Genentech, Inc., South San Francisco, CA, United States.
  • Department of Biochemical and Cellular Pharmacology, Genentech, Inc., South San Francisco, CA, United States.
  • Department of Small Molecule Pharmaceutical Sciences, Genentech, Inc., South San Francisco, CA, United States.
  • Department of Transgenic Technology, Genentech, Inc., South San Francisco, CA, United States.
  • Department of Translational Imaging, Genentech, Inc., South San Francisco, CA, United States.

ORCID-Profile: Martin Weber

Förderung

  • Genentech

Zitieren

APA

Hur, S. K., Leahey, R. R., Geringer, M., Cho, C. H., Hernandez-Barry, H., Pang, J., Sawyer, W. S., Baca, M., Nespi, M., Asuncion, R. R., Choy, M., Maksymetz, J., Vito, S. T., Imperio, J., Stark, K., Green, S. A., Chan, B. K., Xie, L., Ly, J., …, & Weber, M. (2025). Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlaf066

Vancouver

Hur SK, Leahey RR, Geringer M, Cho CH, Hernandez-Barry H, Pang J, et al. Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection. Journal of Neuropathology & Experimental Neurology. 2025. doi:10.1093/jnen/nlaf066

BibTeX
@article{Hur2025,
  author = {Hur, Seong Kwon and Leahey, Rebecca R and Geringer, Mitchell and Cho, Chang Hoon and Hernandez-Barry, Hilda and Pang, Jichu and Sawyer, William S and Baca, Miriam and Nespi, Marika and Asuncion, Raymond R and Choy, ManKin and Maksymetz, James and Vito, Stephen T and Imperio, Jose and Stark, Kimberly and Green, Samantha A and Chan, Bryan K and Xie, Luke and Ly, Justin and Nugent, Alicia A and Hofmann, Jeffrey W and Hinz, Flora I and Weber, Martin},
  title = {Compound muscle action potential as an early functional in vivo measure of Sarm1 inhibition after sciatic nerve transection},
  journal = {Journal of Neuropathology & Experimental Neurology},
  year = {2025},
  doi = {10.1093/jnen/nlaf066}
}
Kostenlos starten →